We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA approved the first fully oral regimen for unfit AML. Learn how the INQOVI+venetoclax combination is changing treatment and quality of life. Details and market outlook.
